PFSweb (NASDAQ:PFSW) and Protagenic Therapeutics (OTCMKTS:PTIX) are both small-cap business services companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.
Volatility & Risk
PFSweb has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Protagenic Therapeutics has a beta of -7.89, indicating that its stock price is 889% less volatile than the S&P 500.
Profitability
This table compares PFSweb and Protagenic Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PFSweb | 0.25% | 12.07% | 3.14% |
| Protagenic Therapeutics | N/A | -3,445.12% | -315.61% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for PFSweb and Protagenic Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PFSweb | 0 | 1 | 3 | 0 | 2.75 |
| Protagenic Therapeutics | 0 | 0 | 0 | 0 | N/A |
PFSweb currently has a consensus price target of $10.33, indicating a potential upside of 179.28%. Given PFSweb’s higher possible upside, equities research analysts plainly believe PFSweb is more favorable than Protagenic Therapeutics.
Institutional & Insider Ownership
57.7% of PFSweb shares are held by institutional investors. 6.5% of PFSweb shares are held by company insiders. Comparatively, 51.1% of Protagenic Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares PFSweb and Protagenic Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PFSweb | $326.16 million | 0.22 | $1.23 million | N/A | N/A |
| Protagenic Therapeutics | N/A | N/A | -$2.56 million | N/A | N/A |
PFSweb has higher revenue and earnings than Protagenic Therapeutics.
Summary
PFSweb beats Protagenic Therapeutics on 9 of the 10 factors compared between the two stocks.
PFSweb Company Profile
PFSweb, Inc. provides omni-channel commerce solutions in the United States, Europe, Canada, and India. It operates through two segments, LiveArea Professional Services and PFS Operations. The company offers strategic commerce consulting services, including commerce strategy, omni-channel consulting, digital opportunity audit, organizational/operational readiness, and platform evaluation/selection services; and design and digital marketing services, such as design, user experience, interactive development, search engine optimization and paid search, affiliate marketing, conversion optimization, storefront management, email marketing, and digital analytics. It also provides technology services comprising commerce development, managed, quality assurance, and training services; and order to cash service, such as technology collaboration, information management services, payments, business-to-business financial management, and direct-to-consumer financial management. In addition, the company offers fulfillment services, including distribution facilities and infrastructure, facility operations and management, pop-up distribution centers, and kitting and assembly services; and customer care services comprising customer service application, customer assistance, quality monitoring, and customer self-help. It serves clients in various industries, such as fashion apparel and accessories, fragrance and beauty products, consumer packaged goods, home furnishings and housewares, coins and collectibles, and technology products. The company was founded in 1999 and is headquartered in Allen, Texas.
Protagenic Therapeutics Company Profile
Protagenic Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics to treat central nervous system disorders. Its lead drug candidate is PT00114, which is in clinical proof-of-concept studies for the treatment-resistant depression and/or post-traumatic stress disorder. The company is based in New York, New York.
Receive News & Ratings for PFSweb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for PFSweb and related companies with MarketBeat.com’s FREE daily email newsletter.